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OBJECTIVES This sub-study of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEG-
RITI) trial evaluated of the impact of combination reperfusion therapy with reduced-dose
tenecteplase plus eptifibatide on continuous ST-segment recovery and angiographic results.
BACKGROUND Combination therapy with reduced-dose fibrinolytics and glycoprotein IIb/IIIa inhibitors for
ST-segment elevation myocardial infarction improves biomarkers of reperfusion success but
has not reduced mortality when compared with full-dose fibrinolytics.
METHODS We evaluated 140 patients enrolled in the INTEGRITI trial with 24-h continuous 12-lead
ST-segment monitoring and angiography at 60 min. The dose-combination regimen of 50%
of standard-dose tenecteplase (0.27 g/kg) plus high-dose eptifibatide (2 boluses of 180
g/kg separated by 10 min, 2.0 g/kg/min infusion) was compared with full-dose tenect-
eplase (0.53 g/kg).
RESULTS The dose-confirmation regimen of reduced-dose tenecteplase plus high-dose eptifibatide was
associated with a faster median time to stable ST-segment recovery (55 vs. 98 min, p 0.06),
improved stable ST-segment recovery by 2 h (89.6% vs. 67.7%, p  0.02), and less recurrent
ischemia (34.0% vs. 57.1%, p  0.05) when compared with full-dose tenecteplase.
Continuously updated ST-segment recovery analyses demonstrated a modest trend toward
greater ST-segment recovery at 30 min (57.7% vs. 40.6%, p  0.13) and 60 min (82.7% vs.
65.6%, p  0.08) with this regimen. These findings correlated with improved angiographic
results at 60 min.
CONCLUSIONS Combination therapy with reduced-dose tenecteplase and eptifibatide leads to faster, more
stable ST-segment recovery and improved angiographic flow patterns, compared with
full-dose tenecteplase. These findings question the relationship between biomarkers of
reperfusion success and clinical outcomes. (J Am Coll Cardiol 2004;43:549–56) © 2004 by
the American College of Cardiology Foundationfl
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olatelet glycoprotein (GP) IIb/IIIa receptor inhibitors have
merged as a promising adjunctive reperfusion therapy for
cute ST-segment elevation myocardial infarction (STEMI)
hen combined with reduced doses of fibrinolytics (termed
combination therapy”), given the central role of activated
latelets in the pathophysiology of intracoronary thrombus
ormation after plaque rupture (1). Recent studies of com-
ination therapy have shown favorable improvements in
iomarkers that indicate early reperfusion success, including
ngiographic Thrombolysis In Myocardial Infarction (TIMI)
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ivision, Brigham and Women’s Hospital, Boston, Massachusetts; ‡John Nasseff
eart Hospital, St. Paul, Minnesota; §Montefiore Medical Center, New York, New
ork; and Robert Wood Johnson Medical School, New Brunswick, New Jersey. This
tudy was funded from research grants from Millennium Pharmaceuticals, Inc.,
ambridge, Massachusetts, and Schering-Plough Research Institute, Kenilworth,
ew Jersey.
Manuscript received June 11, 2003; revised manuscript received August 8, 2003,rccepted September 15, 2003.ow grades and static ST-segment resolution (2–4). Subse-
uent large-scale clinical trials have shown lower frequencies of
on-fatal recurrent ischemic events but have failed to demon-
trate improved survival when combination pharmacologic
eperfusion regimens were compared with full-dose fibrinolytic
onotherapy (5,6). Although the impact of combination
herapy before planned mechanical reperfusion with primary
ercutaneous coronary intervention (PCI) is currently being
tudied, these findings suggest that the impact of combination
herapy on the timing and success of pharmacologic reperfu-
ion in STEMI patients is not fully understood.
Continuous monitoring of ST-segment resolution is a
uantitative biomarker developed to comprehensively eval-
ate the speed, quality, and stability of reperfusion in
atients presenting with STEMI (7,8). Because continuous
T-segment monitoring has been shown to predict recovery
f left ventricular function and clinical outcomes more
eliably than TIMI flow grades, this biomarker may better
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or STEMI (9–12).
Therefore, we performed a continuous ST-segment mon-
toring sub-study as part of the Integrilin and Tenecteplase
n Acute Myocardial Infarction (INTEGRITI) trial to
uantify the speed, stability, and quality of ST-segment
ecovery with reduced-dose tenecteplase combined with the
P IIb/IIIa inhibitor eptifibatide, compared with full-dose
enecteplase monotherapy without eptifibatide, and to de-
ermine how these findings correlated with angiographic
easures of reperfusion success.
ETHODS
atient selection and treatment. All patients presenting to
.S. sites participating in the INTEGRITI trial were eligible
or inclusion in the continuous ST-segment monitoring sub-
tudy. Patients at Canadian and European sites were not
ligible for inclusion, given resource limitations and logistical
hallenges related to training and equipping sites outside of the
.S. Inclusion criteria for the main INTEGRITI trial included
resentation within 6 h of the onset of ischemic chest pain
asting for at least 30 min, persistent ST-segment elevation in
wo or more contiguous electrocardiographic (ECG) leads, and
ge 18 to 75 years (13). Exclusion criteria have been published
reviously.
All patients received aspirin and unfractionated heparin.
reatment with tenecteplase plus eptifibatide was randomly
ssigned based on the phase of the trial. During the
ose-finding phase, patients were assigned to receive vary-
ng doses of both reduced-dose tenecteplase plus eptifi-
atide in two sequential parts (13). The combination of
alf-dose tenecteplase (0.27 mg/kg) and high-dose eptifi-
atide (180-g/kg bolus, 2.0-g/kg/min infusion; second
80-g/kg bolus 10 min later) emerged as the most prom-
sing regimen from the dose-finding phase and was com-
ared with full-dose tenecteplase monotherapy in the dose-
onfirmation phase.
oronary angiography and PCI. All patients underwent
oronary angiography within 60 min (range 55 to 75 min)
fter administration of the tenecteplase bolus, with the
Abbreviations and Acronyms
CTFC  corrected TIMI frame count
ECG  electrocardiogram/electrocardiographic
GP  glycoprotein
IMCL  Ischemia Monitoring Core Laboratory
INTEGRITI  Integrilin and Tenecteplase in Acute
Myocardial Infarction trial
IRA  infarct-related artery
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial
infarction
TIMI  Thrombolysis In Myocardial Infarction
TMPG  TIMI myocardial perfusion graderimary end point of the trial being TIMI flow grade in the pnfarct-related artery (IRA). Angiograms were reviewed in a
linded core laboratory, according to methods previously
ublished (13). The angiographic parameters analyzed in-
luded TIMI flow grade, corrected TIMI frame count
CTFC), and TIMI myocardial perfusion grade (TMPG).
fter angiography, PCI was permitted at the discretion of
he investigator. Post-PCI angiography was recommended
o assess the impact of PCI on angiographic parameters of
eperfusion success, but it was not mandated.
T-segment monitoring. The ST-segment monitoring
as performed with RZ-152 12-lead integrated-circuit
T-segment monitors (Northeast Monitoring, Boston,
assachusetts) that acquired and archived a standard 12-
ead ECG every 60 s and a continuous three-lead Holter
hythm strip every 60 s. Patients were monitored for 24 h
eginning at the time of enrollment in the main INTEG-
ITI trial. Continuous ECG data were not accessible to the
linical care teams at the enrolling sites. Digital ECG data
n 32-megabyte flashcards were analyzed at the Ischemia
onitoring Core Laboratory (IMCL) at Duke Clinical
esearch Institute (Durham, North Carolina).
All studies were analyzed according to the standard methods
f the IMCL. All analyses were done in blinded manner as to
reatment assignments and other clinical information. Analysis
f the ST-segment variables started at the onset of treatment
ith tenecteplase and continued for 24 h. Detailed definitions
f IMCL standard parameters for ST-segment recovery anal-
sis have been published previously (8,14–16). Patients with
echnical inadequacies that obscured ST-segment monitoring,
uch as ECG tracing artifacts or transient left bundle branch
lock, were excluded.
Primary ST-segment recovery parameters were analyzed
uring the 24-h period of monitoring, based on the single
CG lead with maximal ST-segment deviation before the
nset of ST-segment recovery. The degree of ST-segment
levation in the most deviated ECG lead was continuously
ssessed before ST-segment recovery occurred. Time to
table ST-segment recovery was defined as the time from
he onset of lytic therapy to the beginning of a period of
50% recovery from previous peak ST-segment levels in
he most deviated lead, lasting 4 h without further
T-segment evolution (100 V). Recurrent ischemia was
efined as either early cyclic flow or late ST-segment
e-elevation. Cyclic flow (early recurrent ischemia) was
efined as ST-segment re-elevation of 150 V after a
eriod of 50% recovery from previous peak ST-segment
evels in the most deviated lead, but before stable ST-
egment recovery. Late ST-segment re-elevation (late re-
urrent ischemia) was defined as either ST-segment re-
levation of 150 V in the most deviated lead occurring
fter stable ST-segment recovery or persistent ST-segment
levation 6 h after the onset of therapy (i.e., 6 h time to
table ST-segment recovery). The quality of reperfusion was
efined by the percentage of ST-segment recovery at the
ime of steady-state ST-segment recovery relative to the
revious absolute peak ST-segment level. For the purposes
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February 18, 2004:549–56 Combination Reperfusion Therapy for Acute STEMIf this protocol, this was assessed as a continuous variable at
he onset of stable ST-segment recovery at 6 h after the start
f lytic therapy relative to the previous absolute peak
T-segment level (if onset of stable ST-segment recovery
as 6 h). The quality of reperfusion was also assessed as a
ichotomous variable (presence or absence of 50% recov-
ry from the previous peak levels) at 30, 60, 90, 120, and
80 min after lytic therapy. The combination of speed,
tability, and quality of reperfusion was measured as the area
nder the ST-segment deviation versus the time trend curve
uring the first 3 h after the start of lytic therapy.
tatistical analysis and power calculation. The primary
ypothesis was that combination therapy with tenecteplase and
ptifibatide would shorten the time to stable ST-segment
ecovery, compared with full-dose tenecteplase monotherapy.
he secondary hypothesis was that combination therapy with
enecteplase and eptifibatide would: 1) decrease the frequency
f recurrent ischemia denoted by cyclic flow patterns and late
T-segment re-elevation; 2) improve the quality of reperfusion
s assessed by the percent ST-segment recovery from previous
eak levels (continuous and dichotomous measures); and 3)
educe the overall injury pattern as assessed by the ST-segment
eviation trend curve area.
The time of stable ST-segment recovery was collected for
ll patients with analyzable ECG data. Group comparisons
or continuous variables were performed with the two-
ample t test, Wilcoxon rank-sum test, or log-rank test for
ensored data. A comparison of discrete variables was
erformed with the likelihood ratio chi-square test or Fisher
xact text.
This study was powered to achieve statistical significance
or the comparison of treatment groups with regard to the
ime from treatment until stable ST-segment recovery. The
able 1. Baseline and Procedural Characteristics
Variable
Full-Dose TNK
(n  41)
T
Ept
ge (yrs) 55 (50, 65)
ime to treatment (h) 2.8 (2.1, 4.0)
ale gender (%) 80.5
ypertension (%) 41.5
iabetes mellitus (%) 24.4
urrent smoking (%) 48.8
ypercholesterolemia (%) 24.4
revious CHF (%) 0.0
revious MI (%) 9.8
revious PCI (%) 9.8
nfarct-related artery (%)
LAD 26.8
LCx 9.8
RCA 61.0
ABP (%) 9.8
mmediate PCI performed (%) 80.5
Percent reduction in tenecteplase (TNK) dose with combination therapy (normal TNK
f TNK 50% eptifibatide 90/180-g/kg bolus dose, TNK 50% eptifibatide 180/1
alue (25th, 75th percentiles).
CHF  congestive heart failure, IABP  intra-aortic balloon pump; LAD 
ercutaneous coronary intervention; RCA  right coronary artery.ample-size estimates are based on ST-segment recovery wata pooled from previous acute myocardial infarction
linical trials that made a comparison between patients who
eceived a GP IIb/IIIa inhibitor combined with a fibrino-
ytic agent (combination therapy) and patients who only
eceiving fibrinolytics (15,16). Using the pooled ST-
egment recovery data, the sample size of 134 patients was
omputed assuming that combination therapy would de-
rease the median time until stable ST-segment recovery by
0% in the treatment group (hazard ratio 1.67). The overall
ample size was increased by 15% (n  158) to account for
atients in whom ECG data could not be analyzed. The
ample-size calculation was performed using alpha  0.05
two-sided) and beta  0.20 (power 80%). Because there
as no control group in the dose-finding phase, sample-size
alculations were made with the assumption that more
atients would be enrolled in the combination therapy
roup than in the tenecteplase monotherapy group.
Patients who received combination therapy in the dose-
onfirmation phase were analyzed separately and also com-
ined with those from the dose-finding phase for compar-
sons with patients who received full-dose tenecteplase
onotherapy in the dose-confirmation phase.
ESULTS
reatment details. A total of 199 (92%) of the 217
atients enrolled at U.S. sites in the main INTEGRITI trial
ere included in the ST-segment monitoring sub-study,
nd 13 patients who did not receive at least one of the
edications assigned during randomization were excluded
rom the sub-study. Of the remaining 186 patients, the
ontinuous ST-segment monitor was successfully hooked
p in 156 patients (84%), and ST-segment monitoring data
50% or 75%*
ide: 180  90†
 77)
TNK: 50% or 75%*
Eptifibatide: 180  180†
(n  68) p Value‡
(51, 68) 60 (50, 66) 0.52
(2.1, 4.1) 2.9 (2.1, 4.0) 0.90
79.2 67.6 0.19
35.1 25.0 0.18
15.6 14.7 0.38
49.3 50.0 0.99
23.4 27.9 0.81
3.9 0.0 0.12
18.2 16.2 0.48
16.9 17.6 0.50
35.5 26.9 0.48
13.2 10.4
50.0 62.7
14.3 4.4 0.13
68.8 69.1 0.35
0.53 mg/kg). †Eptifibatide bolus doses (g/kg) delivered 10 min apart. ‡Comparison
/kg bolus dose, and full-dose TNK. Continuous variables are presented as the median
nterior descending; LCx  left circumflex; MI  myocardial infarction; PCI NK:
ifibat
(n
57
2.8
dose
80-g
left aere analyzable in 140 (90%) of them. The reasons for
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ncluded development of bundle branch block, technical
rtifacts, late hookup times, or a short duration of monitor-
ng that precluded assessment of ST-segment recovery. The
edian (interquartile) time from administration of the
enecteplase bolus to monitor hookup was0.02 min (7.0
o 13.0). The median duration of ST-segment monitoring
as 23.8 h (23.4 to 24.0).
atient characteristics. Baseline characteristics were sim-
lar across treatment groups for patients enrolled in the
T-segment monitoring sub-study (Table 1). Patients in
hat sub-study underwent immediate PCI after baseline
ngiography more frequently than the overall study cohort
71.5% vs. 58.8%).
T-segment recovery analyses. ST-segment recovery pa-
ameters showed a trend toward an improvement with
ombination therapy across the dosing regimens used in the
ose-finding and dose-confirmation phases (Table 2).
hen patients treated with the dose-confirmation/
ombination therapy regimen (n  68) were compared
irectly to patients who were treated with full-dose tenect-
plase (n  41), combination therapy was associated with a
aster median time to steady-state ST-segment recovery, an
mproved percentage of patients achieving steady-state ST-
egment recovery by 2 h, a smaller median ST-segment
urve area, and less recurrent ischemia. When continuously
pdated ST-segment recovery was analyzed at several static
ime points, modest trends were present for greater ST-
egment recovery at 30, 60, and 90 min with the dose-
able 2. Continuous ST-Segment Recovery Parameters
Variable
Full-Dose TNK
(n  41)
E
ime to first 50% ST-segment recovery (min) 30.5 (0, 54.7)
ime to stable ST-segment recovery (min) 98.0 (0, 148.0)
teady-state ST-segment recovery by 2 h (%) 67.7
T-segment curve area (0–3 h after
treatment) (V/min)
4,858 (598, 13,721)
ecurrent ischemia¶ (%) 57.1
yclic flow (%) 53.3
ate ST-segment elevation (%) 3.4
Percent reduction in tenecteplase (TNK) dose with combination therapy (normal TNK
etween TNK 50% or 75%  eptifibatide 180/90-g/kg bolus doses and full-dose
ull-dose TNK. ¶Recurrent ischemia includes cyclic flow or late ST-segment elevati
Table 3. Static ST-Segment Recovery Paramet
ST-Segment
Resolution
>50%
Full-Dose
TNK
(n  41)
TNK: 50% or 75%
Eptifibatide: 180 
(n  77)
30 min (%) 40.6 52.6
60 min (%) 65.6 71.9
90 min (%) 78.1 84.2
120 min (%) 90.6 87.7
180 min (%) 93.8 89.5
*Percent reduction in tenecteplase (TNK) dose with combina
doses (g/kg) delivered 10 min apart. ‡Comparison between
full-dose TNK. §Comparison between TNK 50%  eptifibatide 1onfirmation/combination therapy regimen as compared
ith full-dose tenecteplase (Table 3).
ngiographic results. Angiographic results at 60 min
emonstrated trends toward improvements in TIMI flow
rades, CTFC, and TMPG across the dosing regimens used
n the dose-finding and dose-confirmation phases, as com-
ared with full-dose tenecteplase (Table 4). After 60-min
ngiography, immediate PCI was performed in more pa-
ients treated with full-dose tenecteplase (Table 1). How-
ver, post-PCI angiography was performed in only 57.6%
19 of 33 patients) versus 56.6% (30 of 53) versus 48.9% (23
f 47) of patients who underwent PCI across the three
reatment groups (full-dose tenecteplase vs. dose-finding
egimen vs. dose-confirmation regimen, respectively; as
hown in Tables 1 and 2). The frequency of TIMI flow
rade 2 or 3 after PCI in patients in whom angiography was
erformed was 89.5% versus 100% versus 95.6%, whereas
he frequency of TMPG 2 or 3 was 52.6% versus 65.5%
ersus 65.2% in the respective dosing groups.
linical outcomes. Despite a higher incidence of mortality
n patients treated with the dose-finding regimen of 50% or
5% of the standard tenecteplase dose with intermediate
oses of eptifibatide (180-g/kg, 90-g/kg double-bolus
egimen), the number of events and sample sizes were small,
nd there were no significant differences in clinical out-
omes among the dosing groups (Table 5). ST-segment
ecovery parameters correlated with the risk of adverse
linical outcomes (e.g., composite of death, re-infarction,
evere congestive heart failure, cardiogenic shock, and ur-
: 50% or 75%*
atide: 180  90†
(n  77) p Value‡
TNK: 50% or 75%*
Eptifibatide: 180  180†
(n  68) p Value§
.8 (0, 40.0) 0.19 13.5 (0, 34.5) 0.05
.5 (8.0, 121.0) 0.55 55.0 (0, 95.0) 0.06
73.6 0.57 89.6 0.02
8 (311, 5,279) 0.09 1,710 (0, 4,156) 0.02
26.5 0.01 34.0 0.05
23.5 0.01 31.2 0.05
4.0 0.90 8.0 0.42
0.53 mg/kg). †Eptifibatide bolus doses (g/kg) delivered 10 min apart. ‡Comparison
. §Comparison between TNK 50%  eptifibatide 180/180-g/kg bolus doses and
ntinuous variables are presented as the median value (25th, 75th percentiles).
p
Value‡
TNK: 50% or 75%*
Eptifibatide: 180  180†
(n  68)
p
Value§
0.28 57.7 0.13
0.54 82.7 0.08
0.47 90.4 0.12
0.68 94.2 0.53
0.50 92.3 0.80
herapy (normal TNK dose 0.53 mg/kg). †Eptifibatide bolus
50% or 75%  eptifibatide 180/90-g/kg bolus doses andTNK
ptifib
24
65
2,81
dose
TNKers
*
90†
tion t
TNK80/180-g/kg bolus doses and full-dose TNK.
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February 18, 2004:549–56 Combination Reperfusion Therapy for Acute STEMIent repeat revascularization through 30 days) as the time to
table ST-segment recovery was faster and the percentage of
atients with stable ST-segment recovery at 2 h was greater
n patients who did not experience an adverse outcome
Table 6). Conversely, patients with adverse outcomes had a
reater frequency of late ST-segment re-elevation.
ISCUSSION
e have demonstrated faster, more stable ST-segment
ecovery with the combination of reduced-dose tenect-
plase and high-dose eptifibatide compared with full-
ose tenecteplase. Favorable trends in the ST-segment
ecovery parameters analyzed in this study also correlated
ith improved angiographic parameters of reperfusion
uccess and clinical outcomes—a finding that further
emonstrates that rapid, stable reperfusion sufficient to
estore oxygen and nutrient delivery to the myocardium is
he key mechanistic step for the successful treatment of
TEMI (17). However, these results also highlight the
ifferential treatment effect of combination therapy on
able 4. Sixty-Minute Angiographic Results for Patients Enrolle
Variable
Full-Dose TNK
(n  41)
TNK: 50% or 75
Eptifibatide: 180 
(n  77)
IMI flow grade
0 20.5% 8.6%
1 5.1% 5.7%
2 33.3% 17.1%
3 41.0% 68.6%
IMI flow grade
0 or 1 25.6% 14.3%
2 or 3 74.4% 85.7%
TFC (s) 43.0 (21.2, 100) 29.0 (20.0, 47.0)
MPG
0 35.9% 24.6%
1 18.0% 17.4%
2 2.6% 1.4%
3 43.6% 56.5%
MPG
0 or 1 53.8% 42.0%
2 or 3 46.2% 58.0%
Percent reduction in tenecteplase (TNK) dose with combination therapy (normal TNK
etween TNK 50% or 75%  eptifibatide 180/90-g/kg bolus doses and full-dose
ull-dose TNK. Continuous variables are presented as the median value (25th, 75th
CTFC  corrected TIMI frame count; TIMI  Thrombolysis In Myocardial In
able 5. Thirty-Day Clinical Outcomes
Full-Dose TNK
(n  41)
TNK: 50
Eptifibatide
(n 
eath 1 (2.4) 8 (
e-infarction 0 2 (
evere CHF 2 (4.9) 6 (
rgent repeat revascularization 3 (7.3) 8 (
ardiogenic shock 0 3 (
omposite of all of the above 5 (12.2) 19 (
Percent reduction in tenecteplase (TNK) dose with combination therapy (normal TNK
etween TNK 50% or 75%  eptifibatide 180/90-g/kg bolus doses and full-dose
ull-dose TNK. Data are presented as the number (%) of patients.CHF  congestive heart failure.iomarkers of reperfusion success compared with clinical
utcomes (2,3,5,6,13,18).
T-segment recovery analyses. Resolution of ST-segment
levation is a simple, non-invasive biomarker that correlates
ith recanalization of the epicardial IRA, successful restoration
f myocardial tissue perfusion, and a lower risk of mortality
19–21). Although frequently reported as measured between
wo serial static ECGs, analysis of static ST-segment resolu-
ion provides only a “snapshot” assessment of reperfusion that
oes not characterize the continuum of reperfusion (21,22). In
ontrast, continuous analysis of ST-segment recovery charac-
erizes the entire process of reperfusion, and ST-segment
ecovery parameters correlate directly to preservation of left
entricular mechanical function, early re-infarction, and mor-
ality (9–12,23). Even though continuous ST-segment mon-
toring analyses have demonstrated improved speed and stabil-
ty of reperfusion with combination therapy, these findings did
ot translate into improved survival in large-scale trials evalu-
ting pharmacologic combination reperfusion regimens
5,6,15,16,24).
the Continuous ST-Segment Monitoring Substudy
p Value‡
TNK: 50% or 75%*
Eptifibatide: 180  180†
(n  68) p Value§
0.03 10.8% 0.11
1.5%
23.1%
64.6%
0.14 12.3% 0.08
87.7%
0.18 30.6 (23.0, 42.0) 0.33
0.56 31.2% 0.38
12.5%
0.0%
56.2%
0.24 43.8% 0.32
56.2%
0.53 mg/kg). †Eptifibatide bolus doses (g/kg) delivered 10 min apart. ‡Comparison
. §Comparison between TNK 50%  eptifibatide 180/180-g/kg bolus doses and
tiles).
n; TMPG  TIMI myocardial perfusion grade.
75%*
 90†
p Value‡
TNK: 50% or 75%*
Eptifibatide: 180  180†
(n  68) p Value§
0.12 0 0.20
0.30 1 (1.5) 0.44
0.55 1 (1.5) 0.29
0.58 8 (11.8) 0.46
0.20 2 (2.9) 0.27
0.11 8 (11.8) 0.95
0.53 mg/kg). †Eptifibatide bolus doses (g/kg) delivered 10 min apart. ‡Comparison
. §Comparison between TNK 50%  eptifibatide 180/180-g/kg bolus doses andd in
%*
90†
dose
TNK
percen% or
: 180
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3.9)
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r continuous ST-segment resolution or angiography alone,
ay be a limited approach to evaluating promising new
eperfusion regimens. Other biomarkers of reperfusion suc-
ess, including infarct size measurements with technetium-
9m sestamibi single-photon emission computed tomogra-
hy, provide complementary information to ST-segment
esolution, but missing or uninterpretable data in 10% to
0% of patients limit the predictive capabilities of individual
iomarkers (2,4,13,22,25). Furthermore, correlations be-
ween individual biomarkers such as ST-segment resolution
nd angiography have not been thoroughly investigated, so
he relative utility of single biomarkers for comprehensively
escribing the speed and quality of reperfusion remains
nclear. Studies that have used multiple, simultaneous
iomarkers suggest that biomarker arrays may be the most
ffective approach for the initial clinical evaluation of new
herapies for STEMI, by both enhancing information
ontent and retrieval and overcoming the loss of data that
ccurs when individual biomarkers are used (26–28). How-
ver, the therapeutic success of new reperfusion regimens
as not yet been tested with biomarker arrays, so strategies
ill need to be developed to determine the optimal number
nd combination of disparate biomarkers that best define
successful” reperfusion and most accurately correlate with
he impact of a given therapy on mortality (29). Thus,
iomarker arrays may be most useful in early phase I and II
rials to assess the biologic activity of new reperfusion
egimens and in mechanistic sub-studies of phase III trials
o provide pathophysiologic underpinnings for the clinical
utcomes results.
ombination reperfusion therapy. Despite the limitations
f using biomarkers to evaluate combination therapy, mech-
nistic studies suggest that combination therapy may offer
everal potential advantages for the treatment of STEMI
atients. The ST-segment resolution analyses have demon-
trated that early reperfusion during the typical “door-to-
alloon” time that precedes primary PCI (30 to 90 min) is
nhanced with combination therapy (3,4,13,24). Because
ortality is substantially lower when normal epicardial flow
s re-established in the IRA before primary PCI is per-
Table 6. Correlations Between ST-Segment R
Variable
N
Time to first 50% recovery (min)
Time to stable ST-segment recovery (min)
Steady-state by 2 h after treatment (%)
ST-segment curve area (0–3 h after treatment)
(V/min)
Recurrent ischemia† (%)
Cyclic flow (%)
Late ST-segment elevation (%)
*Composite of death, re-infarction, severe congestive heart fa
30 days. †Includes cyclic flow or late ST-segment elevation. C
percentiles).ormed and combination therapy reduces angiographic mhrombus burden in the infarct vessel, intensified pharma-
ologic therapy before planned primary PCI may “facilitate”
rimary PCI by enhancing recanalization of the IRA before
CI, improving procedural outcomes, and enhancing myo-
ardial salvage (30–34).
Notwithstanding the potential advantages of a facilitated
harmacologic and mechanical approach for the treatment
f STEMI patients, this study and another continuous
T-segment monitoring study have both shown that com-
ination therapy is associated with a higher rate of late
T-segment re-elevation compared with full-dose fibrino-
ytic monotherapy (24). Because late ST-segment shifts
orrelate with higher mortality, these findings are concern-
ng and suggest that rebound ischemia may occur after
iscontinuation of the heparin or GP IIb/IIIa inhibitor
nfusion (11). A previous study has demonstrated increased
hrombin generation and activity after discontinuation of
eparin following full-dose fibrinolytic therapy, but eptifi-
atide attenuated the risk of rebound ischemia after heparin
iscontinuation in patients with non–ST-segment elevation
cute coronary syndromes (35,36). Nonetheless, precipitants
or recurrent ischemia in relation to the type and duration of
edication regimens used with combination therapy have
ot been investigated. Thus, the benefits of improved early
RA reperfusion with combination therapy may be partially
itigated by late recurrent ischemia, but further studies are
eeded to delineate the causes of recurrent ischemia after
ombination therapy and to determine how recurrent isch-
mia influences clinical outcomes.
tudy limitations. Despite the measurable benefits of
ombination therapy on ST-segment recovery, several lim-
tations were present in this analysis. First, the sample size
as limited (n 140), so a larger study is needed to confirm
hese results. Second, monitors were not placed on approx-
mately 20% of patients enrolled at sub-study sites, and data
ere non-analyzable in an additional 8% of patients who
ere monitored. Strategies for improving data capture and
uality with continuous ST-segment monitoring have al-
eady been developed since the completion of this study,
roducing analyzable rates 90%. Third, the time to
reatment from symptom onset varied among patients and
ry Parameters and Clinical Outcomes
verse Outcome
n  154)
Adverse Outcome*
(n  32) p Value
2.0 (0, 38.0) 31.7 (8.0, 55.0) 0.31
.0 (0, 107.0) 71.0 (25.0, 310.8) 0.01
81.4 57.9 0.02
16 (0, 5,431) 3,267 (168, 7,966) 0.69
38.2 21.4 0.22
36.3 12.5 0.06
3.5 21.4 0.01
ardiogenic shock, or urgent repeat revascularization through
uous variables are presented as the median value (25th, 75thecove
o Ad
(
2
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ilure, c
ontinay have influenced the degree of ST-segment elevation
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February 18, 2004:549–56 Combination Reperfusion Therapy for Acute STEMIdentified during monitoring, but we continuously analyzed
he degree of peak ST-segment elevation before recovery to
ccount for the evolution of ST-segment elevation after the
nitial ischemic insult and the onset of ST-segment moni-
oring relative to the timing of symptoms. Furthermore, the
edian time to treatment from symptom onset was almost
dentical in the three treatment groups. Fourth, the majority
f patients analyzed in this study had non-anterior infarcts,
o the treatment effect of combination therapy may have
een underestimated with the large proportion of smaller
nfarcts. Fifth, although approximately 75% of patients
nderwent early PCI after 60-min angiography in the
arious dosing groups, the differential contributions of
ombination pharmacologic therapy and early PCI on
T-segment recovery and angiographic parameters of reper-
usion success could not be accurately determined, given the
on-randomized use of PCI in the treatment arms, the
on-randomized use of eptifibatide during PCI in patients
reated initially with full-dose tenecteplase, and the lack of
ostprocedural angiographic data in almost half the patients
ho underwent PCI. Finally, Canadian and European sites
tilized PCI after angiography in fewer patients, compared
ith U.S. sites, so exclusion of these sites from the contin-
ous ST-segment monitoring sub-study may have further
iased the results.
onclusions. Combination therapy with reduced-dose te-
ecteplase and high-dose eptifibatide appears to be a prom-
sing reperfusion regimen for the treatment of acute
TEMI. Larger studies and studies of patients with larger
nfarcts are needed to determine if the enhanced speed and
tability of ST-segment recovery and improved angio-
raphic flow patterns demonstrated with this combination
herapy regimen will translate into improved clinical
utcomes.
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